Headline Summary: Wave Life Sciences’ Q1 2026 earnings led to a modest stock gain of +1.6% post-call, suggesting a neutral investor response. Updates showcased steady advancement in both the WVE-007 obesity program and the RNA editing portfolio, with new clinical initiatives and regulatory milestones on track. Key Takeaways:

• WVE-007 progressed to Phase IIa for obesity, with FDA acceptance of the multi-dose portion and trial initiation expected this quarter.
• Early clinical data for 007 showed improvement in body composition—specifically visceral fat loss with muscle preservation—and potential for durable, infrequent dosing.
• RNA editing lead WVE-006 for AATD reached therapeutically relevant AAT restoration in interim data; regulatory feedback on a possible accelerated approval is expected mid-2026.
• An investor update is planned to present additional WVE-006 dosing data, with acute phase responses highlighted as an area of efficacy focus.
• Pipeline expansion continues, including preparation to bring WVE-008 (PNPLA3 liver disease) to the clinic in 2026 and ongoing preclinical work on bifunctional modalities.